SAB Biotherapeutics- Warrants (25/07/2027) Receivables

The latest receivables for SABSW is $1.8M as of June 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside SAB Biotherapeutics- Warrants (25/07/2027)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, SABSW's receivables moved from $0 to $1.8M. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SAB Biotherapeutics- Warrants (25/07/2027)'s operating scale or balance-sheet position.

A receivables figure of $1.8M for SABSW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SABSW's receivables ($1.8M), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.